Skip to main content
myeloMATCH precision medicine trials in myeloid leukemias open to patient enrollment

myeloMATCH precision medicine trials in myeloid leukemias open to patient enrollment

The myeloMATCH North American platform study is now open in Canada and comprises a series of clinical trials to treat patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

More >>
 
CCTG NE2 (STOPNET) neuroendocrine study has officially open in Canada.

CCTG NE2 neuroendocrine study has opened in Canada

The CCTG NE2 STOPNET neuroendocrine study has officially open in Canada. Researchers are investigating whether somatostatin analogues (SSA) are needed after targeted therapy for patients with neuroendocrine tumours.

More >>
 
 CCTG CE9 (LUMOS2) now enrolling Canadian patients.

International brain cancer study CE9 (LUMOS2) now enrolling Canadian patients

CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.

More >>
 
Canadian researchers will test a promising new fecal microbiota treatment on patients to cure advanced melanoma

Canadian researchers will test a promising new fecal microbiota treatment on patients to cure advanced melanoma

ME17 one of the world’s largest randomized controlled clinical trials using fecal microbiota transplantation (FMT) to improve the effectiveness of the standard of care for advanced melanoma.

More >>
 

Planned trials

ALC9

Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)

BLC6

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

BR38

Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

HE2

SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma

MD1

CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)

PAC5

Lanreotide for the Prevention of Postoperative Pancreatic Fistula

PR26

Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)

SC30

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT

SC31

Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)

SRC8

Doxorubicin + Pembrolizumab vs Doxorubicin for Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Recently activated

AL6

MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML

More >>

ALC7

Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials

More >>

ALC8

Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)

More >>

BR36

CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer

More >>

CE9

Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)

More >>

ES3

NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)

More >>

HN13

Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer

More >>

MAC30

Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score More >>

NE2

STOPNET - Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Tumours

More >>

PM2

Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated with Immuno-Oncotherapeutics (CAN-IMPACT-IO)

More >>

PR25

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes

More >>

SC29

Stereotactic Body Radiotherapy (SBRT) vs Conventional Palliative Radiotherapy (CRT) for Participants with Painful Non-Spine Bone Metastases

More >>

VU2

STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study

More >>
Welcome to Patient Representative Michelle Audoin

Welcome to Patient Representative Michelle Audoin

Please join the Patient Representative Committee in welcoming Michelle Audoin who will be supporting the Breast Disease Site committee.

More >>
 
Patient Representative Suzanne Wood

Welcome to Patient Representative Suzanne Wood

CCTG would like to extend a warm welcome to Patient Representative Suzanne Wood who will be supporting the GI disease site committee. Suzanne is from Toronto and was diagnosed with Stage IV Colon cancer in July 2022.

More >>
 
Welcoming new Patient Representative Haydn Bechthold

Welcoming new Patient Representative Haydn Bechthold

CCTG would like to welcome our new Patient Representative Haydn Bechthold who will be supporting the Gastrointestinal Disease Site Committee.

More >>
 
Welcome to Patient Representative Jasmine Heuring

Welcome to Patient Representative Jasmine Heuring

A very warm welcome to Jasmine Heuring who has joined the CCTG Patient Representatives Committee and will be supporting the Adolescents & Young Adults and Sarcoma Disease Site Committees. Jasmine is from Winnipeg Manitoba and is a cancer advocate and healthcare analyst.

More >>